Cetero lashes back at FDA misconduct claims which "discredit" employees
This article was originally published in Scrip
The US CRO Cetero Research has hit back at recent US FDA claims of data falsification at its Houston laboratory, calling the action "difficult to understand" since the CRO raised the issue with the FDA in the first instance.
You may also be interested in...
Perhaps only a man who inherited an enthusiasm for peptides could, without a trace of irony, cast diabetes drug development as the work of a pastry chef. But for David Solomon, the son of a peptide devotee, mixed metaphors and stretched comparisons are simply the spray thrown up by his unbridled enthusiasm for his chosen trade, that of basketball coach to GLP-1 receptor agonist developer Zealand Pharma.
"How the hell will Glaxo need you? You've only got a few people, they've got about 50,000!"